Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01398397 · ClinicalTrials.gov registry record
Medical Record Review of Hypohidrotic Ectodermal Dysplasia Clinical Phenotype
A clinical trial, sponsored by Edimer Pharmaceuticals.
- Completed
- Registry status
- 11
- Enrollment target
NCT01398397: Completed study, sponsored by Edimer Pharmaceuticals.
NCT01398397 is a clinical trial that has completed, run by Edimer Pharmaceuticals. The registered enrollment target is 11 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT01398397 has completed, sponsored by Edimer Pharmaceuticals.
- COMPLETED
- Registry status
- 11 participants
- Enrollment target
Study Summary
This study is being done to collect information about people who have or may have Hypohidrotic Ectodermal Dysplasia (HED) or X-linked Hypohidrotic Ectodermal Dysplasia (XLHED). This study will allow Edimer Pharmaceuticals to know more about HED/XLHED so that hopefully the investigators can develop a drug to treat this condition. In this study Edimer will retrospectively review and abstract (summarize) medical records of people that have or may have HED/XLHED in order to further understand the natural history and disease characteristics.
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 11 participants |
| Start Date | 2011-04 |
What the finished NCT01398397 record still lists
NCT01398397 is an observational study that tracks outcomes without assigning an intervention. The registry caps enrollment at 11 participants, a relatively small participant target.
The record links to 0 conditions, and to 0 interventions.
NCT01398397 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT01398397 about?
NCT01398397 is a clinical study titled "Medical Record Review of Hypohidrotic Ectodermal Dysplasia Clinical Phenotype". This study is being done to collect information about people who have or may have Hypohidrotic Ectodermal Dysplasia (HED) or X-linked Hypohidrotic Ectodermal Dysplasia (XLHED). This study will allow Edimer Pharmaceuticals to know more about HED/XLHED so that hopefully the investigators can develop a...
What is the current status of trial NCT01398397?
This trial is currently completed. The enrollment target is 11 participants. The study started on 2011-04.
Who is sponsoring clinical trial NCT01398397?
This trial is sponsored by Edimer Pharmaceuticals, which has 11 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT03114462 · 11 participants · Phase 1
Trial of Stereotactic HYpofractionateD RadioAblative (HYDRA) Treatment of Laryngeal Cancer
- NCT06039709 · 11 participants · Phase 1
Sonodynamic Therapy in Patients With Recurrent GBM
- NCT06425380 · 11 participants · NA
Pilot Open-Label Trial of Resistant Potato Starch in Patients With Cirrhosis and Overt Hepatic Encephalopathy
- NCT06472661 · 11 participants · Early Phase 1
FUSA With Intratumoral PolyICLC in Regionally Advanced Resectable Melanoma
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia